This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

MLN2201

Takeda Pharmaceutical Company Ltd

Drug Names(s): MLN01, LDP-01

Description: MLN2201 is a humanized monoclonal antibody that targets the beta-2 subunit of integrins, also known as CD18. In preclinical studies, MLN2201 inhibited inflammatory responses by blocking the attachment of beta 2 integrins to their adhesion molecules, thereby limiting the recruitment of white blood cells participating in the inflammatory process.

Deal Structure: Millennium and Xoma partnered in November 2001 to develop MLN2201. Xoma will develop the drug only for vascular inflammatory indications, through the completion of phase II trials.

In April 2008, Takeda Pharmaceutical and Millennium Pharmaceuticals announced that they entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share. The acquisition closed in May 2008.

Partners: XOMA Corporation


MLN2201 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug